Search

Displaying results 2071 - 2080 of 8517 in total
  1. Drug

    Bezitramide

    go.drugbank.com/drugs/DB01459
    ApprovedIllicitWithdrawn

    After cases of fatal overdose in the Netherlands in 2004 the drug was withdrawn from the market. Bezitramide has never been FDA approved and is currently a schedule II drug. … Bezitramide is a narcotic analgesic which was discovered in 1961, clinically tested around the 1970's [A14383], and marketed under the name Burgodin.

  2. Drug

    Sodium lauryl sulfoacetate

    go.drugbank.com/drugs/DB13157
    ApprovedWithdrawn

    Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.

  3. Drug

    Chorionic Gonadotropin (Human)

    go.drugbank.com/drugs/DB09126
    ApprovedInvestigationalVet approved

    The alpha sub-unit is essentially identical to the alpha sub­ units of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha sub-unit … As a drug product, chorionic gonadotropin is a highly purified pyrogen-free preparation obtained from the urine of pregnant females.

  4. Drug

    Sincalide

    go.drugbank.com/drugs/DB09142
    Approved

    It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK-8_. … [A261876] As the product Kinevac (FDA), sincalide is used to stimulate the duodenum, pancreas, and small bowel for cholesterol analysis, enzymatic activity analysis, and x-ray examination respectively

  5. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

  6. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.

  7. Drug

    Bimatoprost

    go.drugbank.com/drugs/DB00905
    ApprovedInvestigational

    It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug

  8. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

  9. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

  10. Drug

    Doxycycline

    go.drugbank.com/drugs/DB00254
    ApprovedInvestigationalVet approved

    [L42880] It is a second-generation tetracycline that was first discovered in 1967.[A19429] Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines.